SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (311)2/24/2003 3:43:10 PM
From: Jibacoa  Respond to of 3722
 
PPHM Is up for its second day on a roll after it announced that it received approval from the FDA to start its Cotara Phase III for glioblastoma. According to the company,this single trial will be sufficient for the FDA to evaluate the efficacy and the safety of Cotara.

The stock is up 20.9% on volume now over the 3M level.(Almost 6x its daily average.)

The stock still needs to close above its Jan.6 H of 0.94 before it can test the Nov.26 H at 1.20

Insiders only hold around 4% and institutions only around 5% and have done very significant selling.<g>The cash/share is around $0.06 and the last Q loss was $0.03/share.<g>

siliconinvestor.com

Bernard



To: Jibacoa who wrote (311)2/25/2003 1:05:41 AM
From: Mike  Read Replies (2) | Respond to of 3722
 
Thanks for the comments and analysis. Would you mind if I posted the information on the MDCO board? Just trying to get the discussion on this stock going. I think the prospect and potential is right. This could be a very good year for MDCO. We will see what the market determines as far as a price.

Thanks again,
Mike


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News